Skip to main content

Table 1 Patient demographics

From: Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database

Characteristics

N (%)

Age group (years)

 < 12

2 (0.10)

 ≥ 12 to < 20

5 (0.20)

 ≥ 20 to < 40

376 (16.10)

 ≥ 40 to < 60

1162 (49.90)

 ≥ 60

784 (33.70)

Gender

 Male

1570 (67.40)

 Female

583 (25.00)

 Gender not disclosed

176 (7.60)

Comorbidities

 Diabetes

679 (29.69)

 Hypertension

465 (20.33)

 Cardiac disease

145 (6.34)

 Lung disease

100 (4.37)

Need for oxygen supplementation

 SLFO

1483 (65.27)

 HFO

433 (19.06)

 NIV

273 (12.02)

 MV

80 (3.52)

Concomitant medications

 Antibiotics

702 (64.90)

 Steroids

518 (47.90)

 Anticoagulants

345 (31.90)

 Vitamin C

246 (22.80)

 Zinc

124 (11.50)

  1. SLFO standard low-flow oxygen, HFO high-flow oxygen, NIV non-invasive ventilation, MV mechanical ventilation